Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.
The company intends to use the proceeds of the round to advance its proprietary enzymatic DNA synthesis technology called EcoDNA.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
Gen9's arrangement with renewable products firm Amyris comes about two months after it launched an access program for its low-cost DNA synthesis services.
Seattle-based chemical manufacturer Arzeda will buy megabase quantities of synthetic DNA from Gen9 for use in developing new advanced molecules.
The Cambridge, Massachusetts-based DNA manufacturer is looking to max out its production capacity, which works best at high volume and throughput.
Agilent will offer its SureVector cloning kits through Eurofins and will supply components for cloning services performed by Eurofins.
The deal is the latest partnership to provide exposure for Cambridge, Massachusetts-based Gen9's BioFab gene synthesis platform.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.